PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identify inhibitors that may enhance the anti-tumor acti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicines
Hauptverfasser: Lee, Jangsoon, Liu, Huey, Pearson, Troy, Iwase, Toshiaki, Fuson, Jon, Lalani, Alshad S., Eli, Lisa D., Diala, Irmina, Tripathy, Debu, Lim, Bora, Ueno, Naoto T.
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8301343/
https://ncbi.nlm.nih.gov/pubmed/34203351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines9070740
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge